Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SPR | P35270 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626318 | 0.97 | KDM4E (0.55) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17741203 | 0.94 | PDE2A (0.50) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17730272 | 0.90 | KDM4E (0.55) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17730269 | 0.90 | KDM4E (0.55) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19626317 | 0.88 | KDM4E (0.54) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17730265 | 0.86 | KDM4E (0.42) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19555629 | 0.83 | KDM4E (0.59) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19579149 | 0.83 | KDM4E (0.59) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17743289 | 0.83 | KDM4E (0.59) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19555656 | 0.80 | KDM4E (0.56) | KDM4ETSHRTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-08-02 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-07-18 | — | — | US | disclosed |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-07-18 | — | — | US | disclosed |
| EP-3452045-A1 | METHODS OF TREATMENT AND COMBINATION THERAPIES USING GCASE ACTIVATOR HETEROBICYCLIC AND RELATED COMPOUNDS | Lysosomal Therapeutics Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| WO-2017192841-A1 | METHODS OF TREATMENT AND COMBINATION THERAPIES USING GCASE ACTIVATOR HETEROBICYCLIC AND RELATED COMPOUNDS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-3215510-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073889-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073889-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | KDM4E 710/4885TSHR 3606/4885TAS1R3 1656/4885 |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | KDM4E 1027/4885TSHR 3615/4885TAS1R3 1781/4885 |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | KDM4E 1027/4885TSHR 3615/4885TAS1R3 1781/4885 |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | KDM4E 1027/4885TSHR 3615/4885TAS1R3 1781/4885 |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | KDM4E 944/4885TSHR 3497/4885TAS1R3 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.